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Introduction. A drug nanosuspension is a versatile technological approach to formulating 
poorly water soluble molecules consisting of 100 % pure drug nanocrystals with sizes in the 
nano-scale range. Nanosuspensions can be obtained with bottom-up and top-down 
methods or by their combination. They can enhance the bioavailability of drugs via various 
administration routes. Due to their sizes, nanosuspensions can be also considered to be 
drug delivery nanotechnologies. 
Area covered. This review focuses on the state of the art of the nanocrystal-based 
formulation. It describes characteristics, design parameters, preparation methods, stability 
issues, as well as specific applications via various administration routes. The potential of 
nanocrystals as  nanomedicine formulation  is also reported. 
Expert opinion. Many drug delivery systems have been developed to increase the 
bioavailability of drugs and to decrease adverse side effects, but few can be industrially 
manufactured. Nanocrystals can be considered versatile means with which to combine 
traditional and innovative drug formulations. Indeed, they can be used in many 
pharmaceutical processes as such, or as nano-scaled carriers. Engineered surface 
nanocrystals have been recently proposed for stability and targeting purposes.  




1. Introduction  
Currently, poor water solubility is one of the most challenging issues in the development of 
new drugs, considering that about 40% of the new chemical entities (NCEs) are practically 
insoluble in water (1). Drug solubility plays a significant role during drug administration, 
especially for oral and parenteral formulations (2, 3) because modifying the solubility makes 
it possible to achieve the concentration of the drug in the blood required to obtain a 
pharmacological response (4). Indeed, orally administered poorly water soluble molecules 
often need high doses to reach therapeutic plasmatic concentrations, with the possibility of 
causing serious dose-related side effects.  
Drug biopharmaceutical properties are described in the Biopharmaceutics Classification 
Systems (BCS) developed by Amidon (5-9), in which drugs are classified into four classes 
according to their solubility and permeability properties (10). Class I includes molecules 
with both high solubility and high permeability; while class II comprises compounds with 
low solubility and high permeability. Class III includes molecules with high solubility but low 
permeability, and class IV compounds in which both poor solubility and poor permeability 
limit drug absorption.  
Consequently, only class I molecules do not entail problems with oral absorption. There are 
several approaches to improving drug solubility (11). They are based on the modification of 
the physico-chemical drug properties, on the use of suitable functional excipients, or on the 
application of various technological strategies. Schematically, solubility enhancement 
methods may be classified as follows: 
a. Modification of the drug medium (e.g. pH, solvent/cosolvent mixture, surfactants) (12, 13) . 
b. Reservoir systems (e.g. cyclodextrin inclusion complexes, lipid formulation) (14, 15) 
c. Solid state modification (e.g. amorphous solid dispersion, size reduction, such as 
micronization, nanosizing, particle engineering)(16, 17). 
d. Nanotechnology drug delivery system (e.g. vesicles, nanoparticles, nanosponges) (18-20). 
Among these approaches, the possibility of developing pure drug nanosuspensions by 
means of nanosizing methods is becoming increasingly important, given their versatility and 
capacity to overcome some formulation drawbacks, such as the large use of additives (21). 
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Therefore nanosuspensions consist of 100% drug crystals with sizes in the submicron range, 
usually dispersed in liquid media, either aqueous or non-aqueous, and stabilized by 
surfactants and polymers (22). 
The addition of stabilizer is necessary to ensure an adequate stability of the formulation, as 
the nanoscaled sizes leads to a larger surface area than that of conventional suspensions.  
Nanocrystals can be classified as belonging to a first and second generation. The first 
generation consists of pure drug nanosuspensions obtained with bottom-up and top-down 
techniques. The second generation includes nanocrystals with improved properties 
achieved with combination technologies. Finally, engineered nanocrystals can be 
considered the third generation. 
Size reduction represents an advantage for poorly water soluble compounds because its 
leads to an enhanced saturation solubility and dissolution rate with the relative improved 
drug bioavailability (17). Recently this formulation strategy has been proposed also for 
medium soluble compounds in order to improve their dermal delivery (23). The rationale 
for this new type of dermal formulation is that nanocrystals can act as fast dissolving 
reservoirs increasing the drug’s saturation solubility. Moreover, the nanometer sizes can 
favour nanocrystal accumulation in the hair follicles. 
Surface-functionalized nanocrystals can be obtained from either the coating or the 
conjugation of targeting ligands and they are under investigation as drug nanocarriers with 
the potential to target specific organs. 
The purpose of this review is to describe nanosuspensions composed of drug nanocrystals 
from a technological point of view, with examples of their application via different routes of  
administration, as well as their use as innovative nanomedicine for drug delivery (Figure 1) 
(24-26).  
1. Physico-chemical background of nanosuspensions 
Size reduction leads to an increased surface area and greater dissolution velocity of a solid, 
particularly from microparticles to nanoparticles, according to the Noyes-Whitney equation 
and to the subsequent Nerst-Brunner and Levich modification (27, 28). 
4 
 
Moreover, particle size reduction can result in the increased saturation solubility of a 
compound.  
In the case of conventional coarse powders, the saturation solubility is a constant which 
depends on the substance, the dissolution medium and the temperature (24). Indeed, the 
saturation solubility of nanoparticles is also a function of the particle size (29), as postulated 
by by the Ostwald- Freundlich equation. 
The Kelvin equation is another mathematical law useful for describing drug behaviour . It 
considers the transition of a molecule from a liquid phase, such as a droplet, to a gas phase; 
and the same thereotical principle can be applied to the molecule’s transition from a solid 
phase, such as nanocrystals, to a liquid phase, for example the dispersion medium (24). 
The increased saturation solubility of drug nanocrystals can enhance the concentration 
gradient between, for example, gut lumen and blood. It consequently improves the 
absorption by passive diffusion (30) of a drug poorly adsorbed in the gastro-intestinal tract. 
Another distinctive characteristic of nanocrystals is their greater adhesiveness to biological 
membranes and tissues, such as the intestinal epithelium. This behaviour has already been 
observed in various nanoparticle systems (21, 31), resulting in a prolonged residence time 
in the gastro-intestinal tract (32, 33). The drug’s nanosuspension adhesiveness can be 
exploited in various administration routes other than the oral one, such as topical, in order 
to improve local and dermal drug delivery. The adhesiveness of nanocrystals can be further 
improved by coating their surface with mucoadhesive polymers. For this purpose, chitosan 
and Carbopol® have been extensively investigated (34-36).  
Recently, surface coated nanocrystals have also been advocated for site-specific targeting 
(21, 37, 38).  
 
2. Methods of preparation  
In regard to the preparation of nanosuspensions, two main approaches, either at lab-scale 
or on an industrial scale, can be used: bottom-up or top-down technologies (Figure 2). The 
former are classified as assembling methods which start with molecules in solution and 
aggregate them into solid particles, which can be crystalline or amorphous. By contrast, 
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top-down technologies are disintegrating methods which start from a coarse material to 
obtain a nanosized formulation.  
 
2.1 Bottom-up technologies 
Bottom-up technologies can be divided between methods based on two different 
strategies: solvent precipitation and controlled evaporation (39, 40).  
The former approach comprises a series of steps: chemical reaction (and the subsequent 
supersaturation), nucleation, solute diffusion and particle growth (39). These processes are 
exploited with different techniques, such as nanoprecipitation or solvent displacement (41), 
pharmaceutical hydrosols (42), high-gravity controlled precipitation (HGCP) (43), flash 
nanoprecipitation (44, 45), supercritical fluid (SCF) technology (46) and sonoprecipitation 
(47). Recently Tran et al. produced isradipine nanosuspensions showing that amplitude and 
time of ultrasonication can markedly affect the sized of the nanocrystals (48). 
Nanoprecipitation is a straightforward process: a lipophilic drug is dissolved in an organic 
solvent, and this solution is then added to a non-solvent for the drug (generally water) in 
which the polar solvent is miscible. This leads to a phase separation with the formation of 
solid drug particles. The organic solvent can be eliminated by evaporation. The 
achievement of very small and monodisperse drug nanocrystals is due to the Ouzo effect 
(41, 49, 50). Rapid addition of the solution to the non-solvent leads to rapid drug 
supersaturation, and to the formation of an ultrafine amorphous (predominantly) or 
crystalline drug. This method involves nuclei formation and crystal growth which are mainly 
dependent on temperature.  
The anti-solvent method is suitable and cost-effective for lab-scale formulation studies, but 
it is not convenient for industrial-scale production, which needs more controllable 
parameters and equipment. 
Nanoparticle growth is the main parameter affecting the nanosuspension’s stability. In 
order to control the process, a wide range of additives for anti-solvent precipitation, 
including polymers (e.g. polyvinyl alcohol, cellulose ethers, chitosan, agar, pectin, and 
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gelatine), sugar (e.g. trehalose), and surfactants (e.g. poloxamers, partial fatty acid esters, 
polyoxyethylene fatty alcohol ethers, and phospholipids), have been investigated (39). 
Bottom-up methods also include technologies based on the controlled evaporation of 
droplets, such as the spray drying technique (51), the aerosol flow reactor method (52) and 
electrospray (53). These approaches are based on evaporation of the solvent from droplets 
obtained from the atomization of a drug solution. The rapid solvent elimination produces 
nanometer-sized particles of the drug. Moreover, the preparation of drug nanosuspensions 
by a solvent quenching technique has also been investigated: briefly, by emulsifying an 
organic solution of the drug in an aqueous solution of a stabilising agent it was possible to 
obtain solid particle formation by rapid displacement of the solvent from the internal to the 
external phase (54, 55). Interestingly, it is possible to control the nanocrystal’s size by 
controlling the size of the emulsion droplets. 
 
2.2 Top-down technologies 
Using these technologies, a coarse material can be nanosized by applying forces. The two 
main top-down techniques are pearl milling and high pressure homogenization. 
The former was developed by Liversidge (16, 39, 56, 57). Generally, pearl mills consist of a 
milling chamber filled with fine milling pearls or media. The container can be static or 
otherwise: in the former milling technique coarse material is moved by a stirrer; in the 
latter, the complete milling chamber is moved, also stirring the milling pearls. Milling media 
can consist of various materials, such as zircon oxide, steel, glass and hard polystyrene.  
A coarse powder can be processed with two different milling approaches: dry milling and 
wet milling. In the former method, the rough material is nanosized in the milling chamber 
by using milling media to obtain a finer product. In the latter, the milling container is filled 
with a pre-suspension obtained from a coarse powder dispersed in an anti-solvent. 
Generally, dry milling is not sufficient to obtain submicron particles. Therefore the wet 
milling process is the one most frequently applied (58). 
Milling time, speed, temperature and drug amount are critical parameters to take into 
account when using the milling technique. For example, a complete milling process can last 
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from hours to several days depending on the desired results (38). Evidently, this can be 
considered a significant limitation of milling technology, especially from an industrial 
perspective (57). 
One of the main drawbacks associated with pearl milling technology is erosion from the 
milling material or from the chamber during the milling process. Various parameters can 
affect the degree of erosion, such as milling time and initial material conditions. Usually, in 
order to deal with this problem, the milling chamber and the milling media are covered 
with specific materials, such as various plastics. 
The easy scalability from laboratory-scale to industrial-scale and its cost effectiveness are 
the most significant advantages of this technique. 
Two products based on the pearl-milling technology are available on the market: 
Rapamune® and Emend®. 
Another important top-down technique is high pressure homogenization, which exploits 
high energy processes to reduce particle dimensions. There are two important 
homogenization technologies: microfluidizer technology and piston gap homogenization 
technology, which can be performed in water or in water mixtures and in non-aqueous 
media (24). 
The jet-stream principle is the basis of the microfluidizer technology (MicrofluidicsTM Inc., 
USA.). In this case, pure drug particles in suspension can be nanosized by making two 
streams of liquid collide. Crystal reduction is obtained by two different mechanisms 
consisting of particle collision and cavitation. The main drawback for industrial-scale 
production is the high number of cycles, from 10 to 500, required during the nanosizing 
process (59). Insoluble Drug Delivery-Particles (IDD-PTM) technology is based on the jet 
stream principle and it belongs to SkyePharma Canada Inc. 
In regard to piston gap homogenization techniques, two main technologies based on this 
principle have been developed by Müller: Dissocubes® (SkyePharma PLC) and Nanopure® 
(Abbot) (60). In the Dissocubes® method an aqueous pre-suspension composed of a drug 
powder and a surfactant is forced by a piston under pressure (typically 1500–2000 bar) 
through a tiny homogenization gap, whose size range is between 5 and 20 µm. The high 
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streaming velocity inside the homogenizer causes an increase in the dynamic pressure and 
a reduction in the static pressure below the vapour pressure of the aqueous phase, as 
described by the Bernoulli equation. This mechanism induces water to start boiling and 
form gas bubbles, which collapse instantaneously when the liquid leaves the 
homogenization gap. Shock waves caused by cavitation can contribute to the disintegration 
of the crystals in suspension.  
The efficiency of the piston gap homogenization technique depends on several critical 
parameters, such as homogenizer pressure, number of homogenization cycles, and 
hardness of the drug (60).  
The Nanopure® technology is an alternative approach based on the piston-gap homogenizer 
exploiting a non-aqueous pre-suspension, in which the liquid medium can be composed of 
oils, PEGs, or mixtures of water and organic solvents (i.e. glycerol–water, ethanol–water). 
These media are characterized by a low vapour pressure which reduces or excludes the 
cavitation phenomenon. Therefore crystal disintegration takes place due to shear forces, 
particle collisions and turbulences induced by the homogenizer. Moreover, the Nanopure® 
process can occur at low temperatures, so temperature-sensitive drugs can be processed. 
Nanosuspensions obtained with this technology are commonly used to fill capsules. 
 
2.3 Combination Technologies 
Generally, these techniques consist in the combination of bottom-up and top-down 
approaches.  
The NANOEDGETM technology (Baxter) involves a first pre-treatment step consisting in the 
precipitation method, with a subsequent annealing step, i.e. high pressure homogenization 
(61). During the annealing step, several types of energy (heat, mechanical) can be applied 
to convert matter into a more stable form in order to prevent the growth of the 
nanocrystals obtained with the precipitation approach. The main drawback of this 
technology concerns the use of organic solvents during the precipitation step and the 
subsequent necessity to remove them, which is a time-consuming and expensive procedure 
from an industrial perspective.  
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Interestingly, clarithromycine nanocrystals were obtained by a method comprising 
precipitation-lyophilization and homogenization (62). This three combination method, 
called PLH, is particularly suitable for compounds that request high pressure and more 
cycles of homogenization for reducing their sizes. The pre-treatment by precipitation can 
reduce the initial particle sizes of the drug and then the lyophilisation step can provide 
more porous and friable particles. Therefore the PLH combination method can permit to 
achieve rapidly nanocrystals decreasing the homogenization cycles.  
The smartCrystal® technology, owned by Abbott and marketed by Soliqs, was developed as 
a “tool box” of various combination processes (63, 64). An improved in vivo performance 
can be obtained through several process variations. H42 is an example of smartCrystal® 
technology: this process is a combination of spray-drying and high pressure techniques. 
Instead, in the H96 process, lyophilization and high pressure homogenization are combined 
in order to obtain nanocrystals with sizes less than 100 nm. 
Despite of the preparation method, the quality and the efficacy of a nanosupension 
formulation must be assessed, and a detailed chemical and physical characterization is 
required. Table 1 reports the key features of drug nanocrystals in suspension relative to the 
principal techniques available to characterize them. The stability of nanosuspensions will be 
discussed in the next paragraph. 
 
3. Stabilization of nanosuspensions  
The stability of nanocrystals is a critical parameter for formulations of this type. The 
nanometer-sized dimensions of drug nanocrystals may be the main drawback of these 
formulations because they give rise to stability issues and also to potential nanotoxicity 
after their administration (65-67). 
Stability issues can be classified as either chemical or physical. Whilst the former are drug-
specific issues related to each molecule with its specific functional groups, the latter are 
formulation-specific limitations depending on the dosage forms. Instability problems with 
nanosuspensions may arise at any phase of the product life cycle: from the preparation of 
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the finished product to its distribution and storage (67). Generally, a solid is more stable 
than a solution; consequently, the chemical degradation is limited. 
 
In vitro stability 
 
The main physical stability issues involved are comparable to those of traditional 
pharmaceutical suspensions, including sedimentation/creaming, agglomeration, crystal 
growth and modification of the crystallinity state. 
The settling velocity of small spherical particles in a fluid is described by Stoke’s Law and 
depend mainly by the radius of the dispersed nanoparticles, the density of the medium and 
the viscosity of the fluid medium. Indeed, the nano-scaled dimensions of nanocrystals can 
ensure a long-term stability influencing the sedimentation rate. Anyway, stability issues 
may also arise from agglomeration phenomena, which can lead to  a rapid particle settling 
producing as a consequence inconsistent dosing.  
Agglomeration is mainly caused by the nanoparticles’ large surface area, related to their 
nano-structure, which determines an increase of surface energy that might cause attraction 
of nanoparticles. Nanocrystal aggregation leads to a reduction in the surface area of the 
system, decreasing consequently the dissolution velocity and modifying the drug 
bioavailability. Another significant stability issue affecting colloidal suspensions is the 
crystal growth usually known as Ostwald ripening, which arises from the particles’ solubility 
dependence on their size. 
A drug concentration gradient is generated between small and large particles due to the 
high saturation solubility affecting small particles. Consequently, molecules diffuse from the 
small particles’ surfaces at higher concentration to layers surrounding larger particles with 
lower drug concentration. Drug crystallization onto the large particles is then induced by 
the supersaturated solution around them causing particle grow.  
Suspensions of drug nanocrystals with a narrow particle size distribution can prolong the 
long-term stability of formulations, reducing the drug concentration gradients between 
smaller and larger particles. Moreover, stabilizer addition, temperature and mechanical 
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agitation can affect Ostwald ripening. The layer-by-layer (LbL) self-assembly coating of 
nanocrystals was recently proposed as  a stabilization  approach to overcome the Ostwald 
ripening instability ( Strydom, Powder Technology, 2014). The process consists of the 
successive deposition of polyelectrolytes of altenating polarities to form  a nanoshell 
around the solid particles by electrostatic interaction. Theeffect of the coating was 
evaluated with four different model drugs: furosemide, isoxyl, rifampicin and paclitaxel to 
prove the versatility of the mechanisms. This manufacturing process produced stable drug 
nanocrystals with a reduced dissolution rate according to the coat thickness…   
Finally, the crystalline state is an another important parameter to be taken into account. It 
describes the nature of the drug nanocrystals. Commonly, drug particles can have a 
crystalline structure or an amorphous state.  Transformation between these two molecular 
states is a common issue affecting a suspension’s stability. By applying forces to reduce 
crystal sizes, an amorphization of the sample can occur ( Willet, Mole pharmaceutics, 2008) 
. For amorphous solids the risk is that the drug crystallizes during storage, changing 
formulation characteristics. Most amorphous particles are unstable because of their high 
energy, and they tend to convert to a crystalline state with a lower energy.  
 Therefore the control of crystallinity is mandatory  during the production processes.  It is 
generally well established that top-down and bottom-up techniques can produce partially 
or completely amorphous (especially with the precipitation approach) nanosuspensions.  
The presence of stabilizer can favour the formation of amorphous layer on nanocrystal 
surfaces. Kayart and van der Mooter investigated the effect of media milling on generation 
of amorphous in the presence of  HPMC using cinnarizine and naproxen as model drugs. 
The media milling in the presence of the polymer can affect the solid state of nanocrystals 
due to the drug-polymer interactions. The study showed an amorphization of naproxen, 
while no amorphous fraction was observed in cinnarizine sample which is not soluble in 
HPMC. Therefore drugs that are more soluble in the stabilizer can form amorphous in a 
greater extent . 
Wu (Langmuir, 2007) showed that nanocoatig can be a way to inhibit the surface 
crystallization of amorphous indomethacin, considering that amorphous solid may 
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crystallize faster at the interface for the higher molecular mobility at the free surface than 
in the bulk. The small thickness of the mobile surface layer suggests that it could be 
immobilized by a coating.  indomethacin nanocrystals were coated with a polymer coating 
formed by a layer-by-layer assembly of opposite charges polyelectrolytes, such as cationic 
poly(dimethyl(diallyl)ammonium chloride), PDDA and anionic sodium 
poly(stirenesulfonate), PSS, or by an ultrathin coating of gold. The results showed that the 
surface crystallization of amorphous indomethacin was inhibited. The coating also inhibited 
the crystal growth of the nanocrystals stabilizing the nanosuspension. 
  
Moreover polymorphism transformation must also be evaluated during  nanosuspension 
formulation development. The conversion of different polymeorph is a possible phase 
transition during milling in the absence of water or other liquid media. It was observed that 
generally in the presence of water amorphizationis difficult probably because water can act 
as plasticizer  lowering the glas transition temperature and favouring a rapid crystallization 
of the material (Willord Carbohydrted Research). 
The addition of ionic or non-ionic surfactants or polymers as  stabilizers are the most 
common approaches to obtain a stable  nanosuspensions  exploiting  electrostatic repulsion 
and steric stabilization. In regard to electrostatic stabilization, the effects of electrolytes on 
colloid stability is described by DLVO theory, which considers the interaction between 
electrostatic repulsive forces and van der Waals attractive forces on particles in suspension. 
The sum of repulsion potential and attraction potential from the van der Waals forces 
results in the total potential energy of the interaction between nanoparticles. 
The electrical potential is commonly termed the Zeta potential (ζ). It is one of the most 
significant parameters used to describe suspension stability. 
Electrostatic stabilization is obtained by the adsorption of ionic surfactants on the 
nanocrystal surface, such as  sodium dodecyl sulfate (SDS), soy lecithin,  sodium cholate and 
sodium docusate. 
Steric stabilization is achieved  by the adsorption of polymers.  
13 
 
The non-ionic surfactants and polymers generally employed  are Pluronic®, Tween® 80, 
polyethylene glycol (PEG), polyvinyl alcohol (PVA) polyvinylpyrrolidone (PVP), and cellulose 
ether derivatives such as hydroxypropyl cellulose (HPC) and hydroxypropyl methylcellulose 
(HPMC) (67). 
Van Eenderbrugh et al investigated 13 structurally different stabilizers at three different 
concentration  to stabilize 9 different  compound nanocrystals. The results showed that 
cellulose derivatives displayed poor stabilization due to their viscosity-limited 
concentration, while Polysorbate 80 and TPGS showed the best stabilizing performance 
(68).  
To obtain the nanoparticle steric stabilization the addition of amphiphilic non-ionic 
stabilizers plays an important role . These molecules has two parts: an anchor segment, 
which is absorbed into the drug nanocrystals and strongly interacts with them, and a tail 
segment which prolongs into the bulk medium. The solvation effect, strong enthalpic 
interaction between the stabilizer and the solvent, is mandatory to achieve steric 
stabilization and to avoid particle agglomeration in the suspension. Temperature and the 
stabilizer concentration are the most significant limiting factors affecting the solvation 
effects on the stabilizer molecule, as well as the interaction between particles and 
stabilizer. Appropriate intermolecular interactions between the drug  and the polymer 
molecules are a key factor in preventing aggregation. 
The main disadvantage of the steric stabilization mechanism is that the stabilizer choice is 
strongly dependent on drug-specific molecular structure. Therefore current surfactant 
screening methods are based on empirical observations. However, steric stabilization is 
generally the first choice because it is less susceptible to electrolytes in the gut or blood 
(59). 
Recently Ochi evaluated a series of hydrophilic polymers as aggregation inhibitors of  
meloxicam nanocrystals (69). The crystal growth inhibition in a supersaturated drug 
solution was determined  in order to select the most suitable macromolecules. The 
screening rationale is that the polymer that inhibited crystal growth in a supersaturated 
solution is able to prevent aggregation (70). PVP K30 showed the best performance as 
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stabilizers. Then PVP/meloxicam nanocrystals prepared by wet milling were orally 
administered to rats. The oral  administration showed a five-fold increase of the meloxicam 
bioavailability in the presence of PVP compared to the coarse drug powder.  
The possibility to combine the electrostatic and the steric stabilization approaches has also 
been proposed, for examples nanocrystal stabilized by SDS and Poloxamer have been 
described (71). 
Lecithin was used in combination with poloxomer 188  to stabilize amoitone B, an 
anticancer agent. 
The weight ratio (1:1) produced a stable formulation (72). The use of albumin or polymer 
derivatives of aminoacids for the nanocrystal stabilization has also been reported (73). 
Other interesting strategies to stabilize nanocrystal have been developed: the use of 
various cyclodextrins without adding any surfactants, and the engineering of particle 
surface. Hong et al used 2-hydroxypropyl β-cyclodextrin alone or combined with other 
stabilizers to stabilize myricetin nanoscrystals (74). The Authors showed that the 
combination of 2-hydroxypropyl β-cyclodextrin with TPGS  produced a superior stabilization 
than the cyclodextrin alone. 
 It is noteworthy that the presence of other excipients in the nanosuspension, such as 
preservatives, can  modify  the formulation stability by affecting the stabilizer agent’s 
activity (23). 
The possibility of producing self-stabilized nanosuspensions without stabilizers has also 
been investigated, although it is well known that stabilizers play a key role in preventing 
particle agglomeration .  
Another stabilization strategy consists in the transformation of liquid nanosuspensions into 
solid forms, i.e. nanocrystal powders. Freeze-drying, spray-drying, pelletization and 
granulation are the solidification methods most widely used in the pharmaceutical field to 
obtain powders. These powders can be used as solid dosage forms as such, or as injectables 
after  reconstitution or as oral powders. On the other hand, solid nanocrystals can be used 
to fill capsules, or they can be compressed into tablets preserving their properties. 
Moschwitzer  proposed coated pellets as carriers of mucoadhesive nanocrystals of 
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hydrocortisone acetate surrounded  with an enteric coating to achieve a controlled drug 
release (75). 
Bulking agents, such as water-soluble sugars, are usually added to nanosupensions before 
the solidification process in order to maintain the physical-chemical properties of 
nanocrystals.  Burgess and colleagues have recently evaluated the effects of a series of 
sugars and bulking agents in preventing nanocrystal aggregation during freeze-drying or 
spray-drying. They show that the combination of small sugars and polymers yields non-
aggregate nanocrystal powders (76). 
 
5. Applications of nanosuspensions  
The characteristics of nanocrystals enable their administration by all the routes generally 
used. 
Several research works focus on drug nanocrystal development for a specific route of 
administration. Some case studies are reported below. 
 
5.1. Oral route 
After oral administration, besides poor solubility and low permeability, another critical 
factor limiting absorption is the dissolution rate, i.e. the rate at which a solid drug or a drug 
in a formulation passes into solution (10). Since the drug’s transit through the intestine 
occurs in a given time, the drug dissolution rate must be faster than the transit in order to 
maximize the absorption. 
The most representative equation describing drug dissolution is the Noyes Whitney 
equation (27). The dissolution rate is a function of the concentration gradient across the 
layer, the width of the diffusion layer, the surface area of contact of the solid with the 
dissolution fluid and the diffusion rate of the drug in water. The concentration gradient in 
turn is a function of the maximum drug concentration at the surface of the dissolving solid 
and the concentration in the well-stirred bulk . 
In particular for BCS class II compounds, the bioavailability may be enhanced by improving 
the solubility and dissolution rate of the drug in the gastro-intestinal fluids. The nanocrystal 
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technological approach makes it possible to obtain an increased drug dissolution rate and 
increased drug absorption in the gut lumen.  
G.G Liversidge (77) compared a danazol nanosuspension, obtained with a ball milling 
process, with a conventional suspension of the drug, demonstrating that the 
nanosuspension increased oral bioavailability in beagle dogs. Moreover, the bioavailability 
of danazol nanosuspension was not significantly different from that of the cyclodextrin 
complex of the drug. 
Moreover, Liversidge demonstrated that, by decreasing drug particle sizes in the submicron 
range and stabilizing the particles in suspension, it was possible to achieve a significant 
reduction of the gastric irritation caused by oral administration of naproxen. The reduced 
irritation and the improved rate of absorption were attributed to the decreased crystal 
sizes (78). 
Jinno et al. (29) investigated the effects of particle size on the dissolution and oral 
absorption of cilostazol. They focused on several suspension formulations with different 
particle size distributions, prepared with various technological approaches from hammer-
milling, jet-milling to NanoCrystal®. The results showed that the in vitro dissolution rate of 
cilostazol was significantly increased by reducing the particle size, indicating that the 
NanoCrystal® technology is an efficient means with which to improve the oral 
bioavailability of cilostazol and to avoid the food effect on the absorption. 
The development of an oral rutin nanocrystal formulation has been particularly 
investigated. Mauludin din et al. (79) evaluated  the possibility of obtaining dried rutin 
nanocrystals from a drug nanosuspension prepared with high pressure homogenization 
technology. Improved oral dissolution was observed on using dried rutin nanocrystals-
loaded tablets. The improved physicochemical properties of dried rutin nanocrystals 
resulted in increased absorption and bioavailability in the gastrointestinal tract (71). In 
addition, rutin liquid nanosuspension has been investigated over time in order to assess its 
physico-chemical stability (80). The results showed that nanosuspensions obtained with 
high pressure homogenization can protect drugs from chemical degradation. In another 
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work the possibility of formulating quercetin, another flavonoid, as nanocrystals has been 
assessed . 
Buparvaquone nanosuspension for oral administration has also been considered by Müller 
et al. (33). For this purpose, the nanosuspension was incorporated in mucoadhesive 
hydrogels, composed by different types of Carbopol® and chitosan, in order to increase the 
nanocrystals’ adhesiveness in the treatment of the intestinal parasite Cryptosporidium 
parvum. 
Another adhesive nanosuspension has been developed by Kayser et al. (81) by employing 
the high pressure homogenization technique to prepare amphothericin B nanocrystals with 
a mean diameter of about 500 nm. The in vivo efficacy of amphotericin B was improved 
with nanosuspension formulation. 
Currently, several studies consider the possibility of modifying the nanocrystal surface in 
order to enhance their properties . To this end, Patel et al. (82) have developed an 
innovative formulation consisting of positively charged paclitaxel nanocrystals prepared by 
sonoprecipitation with a high pressure homogenization technique, and with an arginine-
based surfactant as a stabilizer.  
 
5.2 Parenteral route 
Drug nanocrystals in suspension can be administered via several parenteral routes, from 
intravenous  to intraperitoneal injections (22), because they can be sterilized by the current 
sterilization methods. Nevertheless, during the development of a parenteral 
nanosuspension, several requirements must be considered, more than in oral applications.  
Firstly, the nanocrystals’ dimensions must range below 5 µm to avoid capillary blockage. 
Moreover, only a few surfactants and polymers can be safely administered parenterally, 
making it difficult to stabilize a nanocrystals system; among them are lecithin, Poloxamer 
188, Tween 80, low molecular weight polyvinylpyrrolidone (PVP) and sodium glycocholate. 
Several intravenous formulation developments have been reported. Moreover as already 
discussed, INVEGA SUSTENNA® is the only marketed product intended for parenteral use. 
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In order to deal with itraconazole’s poor water solubility, Rabinow and co-workers 
investigated a tandem process of microcrystallization followed by homogenization to obtain 
an intravenous drug nanosuspension enhancing the efficacy of the antifungal agent (83) . 
Möschwitzer et al. developed an intravenous omeoprazole formulation using the 
DissoCubes® technology. They achieved a more stable and high concentrated omeoprazole 
nanosuspension, thereby overcoming the chemical drug’s degradability (84).  
Danhier et al have recently investigated nanosuspension as a possible delivery method for 
an innovative poorly water soluble anti-cancer multi-targeted kinase inhibitor. They also 
compared nanosuspension formulation with other technological approaches, assessing its 
potentiality as a possible intravenous injection formulation and its higher efficacy (85). Liu 
et al. have recently studied the novel compound riccardin D, a potential poorly soluble 
anticancer drug. Both the bottom-up method and the top-down approach were used to 
develop an intravenous riccardin nanosuspensions(86). The following are other references 
on the development of intravenous nanosuspensions (87-89). 
 
5.3 Pulmonary route 
The pulmonary administration route has several advantages over other routes. It can be 
used to overcome  first-pass hepatic metabolism, thereby reducing dose and side effects, 
and to treat respiratory disease locally. On the other hand, systemic treatment is possible 
as well, due to the large pulmonary surface areas and rich blood circulation which allow for 
fast drug absorption. 
Nevertheless, nanoparticles in pulmonary delivery are still rare. Most of the published 
research focuses on inhaled drug nanoparticles deal with polymeric nanoparticles, 
liposomes, and solid lipid nanoparticles. There are only a few papers on the pulmonary 
delivery of drug nanocrystals. In order to produce an ideal respirable aqueous suspension, 
solid particles in the liquid dispersion should be below 1-5 µm. 
Both pearl milling and high pressure homogenization technologies have been investigated 
to obtain pulmonary nanosuspensions. 
19 
 
For example, various studies report the processing of beclomethasone dipropionate with 
the ball milling approach (NanoCrystals™) to obtain stabilized nanosuspensions for 
pulmonary administration (90, 91). The possibility of obtaining a relatively stable aqueous 
hydrocortisone nanosuspension by bottom-up technology, using microfluidic reactors, has 
also been examined (92). 
A budesonide nanosuspension for pulmonary administration was purposely tuned by 
Jacobs and coworkers (93). Challenging factors of this formulation were nebulization of the 
nanosuspension in order to permit administration to the lungs, and its long-term stability. 
Nanocrystal characterization before and after aerosolization confirmed suitability for 
pulmonary delivery.  
Itarconazole, a new inhalation-optimized dry powder for the treatment of invasive 
pulmonary aspergillosis, has also been investigated by processing the drug with high 
pressure homogenization (94). For further details on the pulmonary delivery of 
nanosuspensions, the reader is referred to (95). 
 
5.4 Topical route: from skin to ocular delivery 
Generally, nanosuspension is considered suitable for dermal applications because of its 
ability to increase the penetration of poorly water soluble compounds into the skin. The 
first cosmetic product with rutin nanocrystals was marketed in 2007 (JUVEDICAL, Juvena 
Switzerland). 
Nanosuspensions of the anti-oxidant resveratrol have been produced for dermal 
application by Kobierski et al. using high pressure homogenization (96). More recently, 
Shaal and co-workers have developed an hesperitin nanocrystals dermal formulation after 
investigating the influence of several preservatives on the stability of the product (97). 
The ocular administration of poorly water-soluble drugs is considered a significant 
technological issue. The nanosuspension approach can increase corneal drug tissue levels, 
and thus bioavailability (98). Moreover, the reduced use of formulation additives makes 
nanosuspension a promising ophthalmic dosage form with which to decrease ocular 
irritation after administration. For this purpose, Kim and co-workers developed a novel 
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ophthalmic cyclosporin A-loaded nanosuspension using a top-down technique  decreasing 
the ocular irritation in comparison with a commercial product (99) .  Bottom-up approaches 
to obtain ocular nanosuspension have also been investigated. A diclofenac-loaded Eudragit 
S100-based nanosuspension was prepared by nanoprecipitation method by Ahuja et al. 
(100). 
Recently the possibility to formulate dermal preparations based on nanocrystals of medium 
soluble molecules has been also investigated (101). In particular Zhai and colleagues 
proposed an innovative production process able to product physically stable nanocrystals 
from actives with medium solubility (23). In this research work the dermal administration of 
caffeine nanocrystals was studied, promoting the hair stimulation, by the beneficial 
nanocrystals accumulation in the hair follicles. 
 
5. Surface-modified nanocrystal formulations 
Nanocrystals have been also investigated as potential tool in the advanced nanomedicine 
field, as nanotechnological approach, not only for drug delivery but also for diagnosis 
(Figure 3). Thanks to this versatility, nanocrystals represent a good multitasking platform, 
able to evolve from the conventional to the innovative pharmaceutical formulations, 
through chemical modification of their surface.  
First of all, due to their dimensions nanocrystals can be proposed as carrier-free drug 
nanodelivery systems, encapsulating over 99% of the active pharmaceutical molecule with 
a high ratio of drug to excipient (102). Moreover nanoparticles provides some benefits over 
microparticles, such as controlled drug release, modification of pharmacokinetics, 
biodistribution and cellular trafficking. Engineered formulations comprising surface-
modified nanocrystals have been recently designed to improve their properties and 
biopharmaceutical parameters (103). Nanocrystals can be targeted in specific region of the 
body by the modification of  their size and their surface. The localization of the drug at the 
disease site can improve its therapeutic index. 
For instance surface-modified nanocrystals have been investigated in the anticancer field, 
where their small sizes may be exploited for passive targeting by the accumulation of 
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nanoparticles in tumor tissues. In fact, nanocrystals might reach the tumour site through 
the blood stream taking advantage of the enhanced permeability and retention (EPR) 
effect, due to the defective vascular architecture of the tumour tissue and poor lymphatic 
drenage (104).  
Both coating and chemical conjugation approaches have been proposed to modify the 
nanocrystal surface (Figure 4). Staufenbiel and Müller developed an azithromycin 
nanocrystal formulation for i.v. administration by evaluating the influence of different 
coating agents on the protein adsorption patterns (105). Shubar developed surface-
modified atovaquone nanocrystals for the treatment of toxoplasmosis infections by 
eradicating the parasite from the brain. For this purpose Apolipoprotein E, a protein with its 
receptor on the blood brain barrier (BBB), was attached to the nanocrystal’s surface (106). 
Moreover the surface of atovaquone nanocrystals was also modified by the addition of 
poloxamer 188 and sodium dodecyl sulfate to improve oral bioavailability and passage 
through the blood-brain barrier, leading to an improvement in the treatment of 
toxoplasmic encephalitis and other cerebral diseases (107). 
The surface of nevirapine nanocrystals has been modified with various substances, such as 
albumin, dextran and poly(ethylene)glycol (PEG). The albumin-coated system exhibited a 
four-fold increase in macrophage uptake, in respect to the free drug. Shegokar and co-
workers demonstrated that the in vivo biodistribution of surface-modified nevirapine 
nanocrystals increased the drug accumulation in various organs, such as liver, spleen and 
brain, compared with drug solution after intravenous administration to rats (108). 
Wang developed docetaxel nanocrystals coated with soy lecithin showing an increased 
accumulation of the drug at the tumor site after intravenous adminstration to rats (109).  
Moreover the nanocrystal surface can be modified with fluorescent molecules to obtain a 
labelled system for diagnostic purposes. Recently, Hollis et al designed nanocrystals in 
which imaging agents are incorporated in the crystal lattice obtaining hybrid nanocrystals 
(110). They can be considered a theranostic systems permitting simultaneously an 
anticancer treatment and the imaging of the real-time evaluation of the nanocrystal 
biodistribution. For this purpose tritium-loaded paclitaxel nanocrystals with an optical dye 
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physically entrapped in the structure were prepared by nanoprecipitation spiking the drug 
solution with the imaging probe.  Subsequently  the  nanocrystals underwent to 
homogenization to achieve size uniformity. These hybrid nanocrystals were injected 
intravenously in a mouse xenograft model. Whole-body optical imaging of animals  was 
carried out. It was found that only 1% of the injected dose was accumulated in the tumor 
tissues. 
Finally, selective ligands for active targeting can be linked to nanocrystals (111). Leroux and 
colleagues prepared targeted nanocrystals by the chemical bonding of crosslinkable 
polymers on the nanocrystal surface. Briefly, functional copolymers bearing alkynyl or azido 
groups which may prevent aggregation and alter circulation time of drug nanocrystals by 
“click-chemistry” mediated cross-linking (112). 
Liu prepared targeted paclitaxel nanocrystals (102)  by conjugating a folic acid ligand to 
Pluronic F127  used as nanoparticle coating obtaining a new nanomedicine formulation 
with a target therapeutic effect. 
 
6. Products on the market and conclusions 
In regard to nanocrystal formulations currently on the market, the most significant products 
have been developed for oral administration because of its easier requirements compared 
with the parenteral route. Most of the nanocrystal products are obtained using the pearl 
mill technology developed by Elan Nanosystems (24). In 2000 the first formulation 
Rapamune® was placed on market by Wyeth Pharmaceutical. It consists of nanocrystal 
tablets containing sirolimus in a low dose: nanocrystals are released from tablets as an 
ultrafine suspension. Merck introduced the second product Emend® in 2001: it consists of 
an aprepitant hard gelatin capsule filled with a single drug nanocrystal dose incorporated 
into pellets.  
In 2004 the FDA approved the TriCor®, fenofibrate tablets for hypercholesterolemia 
marketed by Abbott Laboratories. Fenofibrate nanocrystals are also formulated as tablets in 
the SkyePharma Triglide: in this case nanocrystals are obtained with IDD-P® technology and 
marketed by Sciele Pharma Inc. (Atlanta, CA, USA).  
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Megace ES® (where ES stands for enhanced solubility) developed by Par Pharmaceutical 
Companies Inc., is a liquid oral nanosuspension for the delivery of megestrol acetate, an 
antianorexic agent. Megace ES has improved the original conventional Megace product by 
utilizing NanoCrystal® Technology (113). Megace ES can be administered in a smaller 
volume with a viscosity lower than conventional Megace suspension. This may be 
important for patients affected by loss of appetite, who typically have difficulty in 
swallowing (114).  
As regards nanocrystal pharmaceutical dosage forms different from oral administration, 
INVEGA® SUSTENNA® (paliperidone palmitate) has been available since 2009 (Janssen). This 
is an extended-release injectable suspension for schizophrenia treatment in adults. INVEGA 
SUSTENNA® was developed by utilizing NanoCrystal® Technology (Elan Drug Technologies' 
proprietary), and it is an aqueous nanosuspension for once-monthly intramuscular 
administration which provides an increased rate of dissolution.  INVEGA SUSTENNA® is 
supplied as a pre-filled syringe which does not require reconstitution or refrigeration. After 
the administration, it acts as a drug reservoir providing an extend release over time. 
These are the nanocrystal-based products on the market, but it should be emphasised that 
several products are now in the pre-clinical and clinical phases and are expected to reach 
the market in the next few years. This tendency underlines the concept that drug 
nanocrystals are one of the most promising approaches in the delivery field to improve the 
administration of drugs. This formulation method may be also applied to obtain 
nanomedicine products with easy manufacturing processes and further potential 




7. Expert Opinion 
Currently much research is focused on the development of drug nanocrystals, seeking 
updated products and new engineered nanocrystal formulations. 
Drug nanosuspensions can be considered versatile delivery platforms combining traditional 
and innovative pharmaceutical products. Their distinctive advantage is the capacity to solve 
biopharmaceutical issues, such as low bioavailability after oral or dermal administration, 
and the potential to decrease the amount of the drug administered and thus reduce 
adverse side effects. 
Drug nanocrystals can be easily translated from lab-scale to industry scale by using 
conventional equipment and preparation methods. As such, they can be a user-friendly 
liquid product or a component of conventional dosage forms.  
The tunable doses and the easy oral administration of drug nanosuspensions make them 
particularly interesting for the preparation of pediatric formulations and for patients with 
swallowing difficulties. Moreover nanocrystals possess a meal-independent drug 
absorption, reducing bioavailability between fed and unfed conditions. Indeed, the 
adhesive properties of nanocrystals play a key role in this mechanism by making 
nanocrystal formulations not sensitive to the food effect.  
The key role in nanocrystal stability is played by the addition of stabilizers. Alternatively, to 
improve stability, nanocrystals can be freeze-dried to obtain a powder that can be used as a 
component of conventional dosage forms such as tablets or capsules. 
On the other hand, nanocrystals can be considered as nanoparticulate carriers with the 
relative advantages. 
Nanocrystals may be considered superior to other colloidal drug delivery systems due to 
their composition, consisting 100% of pure drug, which reduces excipient use and the 
potential safety issues related to them. They can overcome the limitation of a low drug 
payload and modify pharmacokinetic parameters and biodistribution. 
The adhesiveness of nanocrystals should be emphasised. Their strong adhesion capacity is 
due to their increased contact area provided by their higher surface area and van der Waals 
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interactions. This behaviour  can be exploited both in oral administration, to increase 
absorption through the gastro-intestinal tract, and in local administration, dermal, ocular or 
pulmonary, to achieve a more effective and sustained therapeutic response due to the 
prolonged contact time of the drug at site of action.  
The intrinsic adhesiveness capacity can be improved by coating nanocrystals with certain 
polymers. In recent years also the possibility of engineering the nanocrystal’s surface has 
been investigated, the purpose being to improve the in vivo performance of nanocrystals or 
to enhance their physico-chemical stability over time, or for targeting purposes.  
Nevertheless, the nanoparticle-like behaviour of drug nanosuspensions also has some 
drawbacks especially related to potential nanotoxicity after their administration. In fact, 
drug nanocrystals may easily enter into cells, because their sizes regulate the uptake of 
particles. Moreover, their complete and very rapid dissolution may cause negative systemic 
effects in the organism. 
Anyway nanocrystals are considered a low risk class for sizes and dissolution rate (37). 
Nevertheless, nanomedicine formulation will grow in the future, and drug nanocrystals can 
represent the ‘zip tool’ between the traditional pharmaceutical formulations and the 
innovative ones. To date, nanocrystal technology has been mainly investigated for the 
delivery of poorly-water soluble drugs, because of their bioavailability limitations affecting 
their in vivo performance, but they can be used to produce commercial products.  
In the future the application of nanocrystal technological approach might be deeply 
investigated in order to include also the formulations based on medium water-soluble 
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Measured parameters Techniques 
Particle size and size distribution PCS/DLS 
Laser diffraction 
Coulter counter 
Particle size and morphology SEM/TEM 
AFM 
Sedimentation/creaming Visual observation/ laser 
backscattering/ 
near infrared transmission 
Particle surface charge/zeta 
potential 
Laser Doppler electrophoresis 
Crystallinity state XRD/DSC 
Chemical stability HPLC/FTIR/NMR/MS 
 




Figure 1: General overview of the main properties of nanosuspensions as versatile drug 
delivery platform 
Figure 2 Main approaches used in the nanosuspensions production,  either at lab-scale or 
on an industrial scale, classified into bottom-up and top-down technologies. 
Figure 3 Schematic overview of the nanocrystal applications as a versatile zip tool, useful to 
link traditional pharmaceutical formulations and nanomedicine 
Figure 4 Schematic representation of a coated nanocrystal and a engineered nanocrystal, 
representing the third generation of nanocrystals 
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